In 2011, the FDA approved a drug that many hoped would be the first step forward in blood thinning medication since Coumadin’s debut in the 1960s: Xarelto.
Created by Johnson & Johnson and Bayer, Xarelto has been responsible for over $3.2 billion in profits for its manufacturers and developers. It has also become Bayer’s top-selling medication ever. Yet despite its successes on paper, the reality is that more than 18,000 ...
continue reading...
The U.S. Food and Drug Administration (FDA) has given Boehringer Ingelheim’s antidote to its problematic anticoagulant drug Pradaxa a fast-track review, FiercePhrama reports. According to the company, this will make Pradaxa the first “next generation” anticoagulant to receive an FDA-approved antidote.
Last year, the German drug manufacturer Boehringer Ingelheim agreed to pay $650 million to settle roughly 4,000 Pradaxa lawsuits in state and federal courts. Plaintiffs ...
continue reading...
A California man has filed a Xarelto lawsuit against multiple pharmaceutical companies for damages allegedly caused by the blood-thinning medication. The plaintiff claims that the defendants, including Johnson & Johnson’s Janssen Pharmaceuticals, overstated the efficacy and safety of Xarelto. The complaint alleges that no antidote exists for Xarelto in the event of hemorrhagic complications.
Like plaintiffs in other Xarelto lawsuits, the California man alleges that the defendants failed ...
continue reading...Xarelto plaintiffs are asking that federal lawsuits be consolidated in East St. Louis, IL. Bloomberg reports that there are approximately 50 cases filed in 15 different federal courts to date. The plaintiffs have requested that a multidistrict litigation be formed to help move the cases along more efficiently.
Xarelto is a blood thinner that was first approved for use in 2011. The medication is intended to prevent blood clots in patients undergoing ...
continue reading...
Bayer AG, a large German pharmaceutical company, is facing its first lawsuits in the United States over its anti-clotting drug Xarelto. A June 14 article reported that there are fewer than 10 Xarelto lawsuits currently filed.
In July 2011, the FDA approved Xarelto to prevent deep vein thrombosis in patients having knee or hip replacement surgery. In November 2012, the drug was approved to prevent pulmonary embolisms. In ...
continue reading...Boehringer Ingelheim Pharmaceuticals, Inc., manufacturer of Pradaxa, has agreed to pay $650 million to settle Pradaxa lawsuits filed on behalf of approximately 4,000 injured plaintiffs. Managing partner Ramon Lopez serves on the Plaintiffs Steering Committees both for the Illinois Multi District Litigation and the California State Coordinated Actions. Mr. Lopez played an important role in the pretrial and discovery proceedings that led to the settlement agreement, and helped to negotiate the settlement on behalf of ...
continue reading...
